Xeris Biopharma Holdings, Inc. (XERS)
| Market Cap | 1.05B |
| Revenue (ttm) | 291.85M |
| Net Income (ttm) | 554,000 |
| Shares Out | 172.43M |
| EPS (ttm) | 0.00 |
| PE Ratio | 1,898.97 |
| Forward PE | 51.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 953,263 |
| Open | 6.12 |
| Previous Close | 6.12 |
| Day's Range | 6.02 - 6.17 |
| 52-Week Range | 4.26 - 10.08 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 10.83 (+77.83%) |
| Earnings Date | May 7, 2026 |
About XERS
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for XERS stock is "Buy." The 12-month stock price target is $10.83, which is an increase of 77.83% from the latest price.
News
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 44% to $292 million in 2025, with RECORLEV driving growth and a strong pipeline led by XP-8121 entering phase III. Investments in commercial expansion and R&D are expected to sustain momentum, while robust IP and a strengthened balance sheet support long-term targets.
Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025
Achieved record revenue and first full-year net income in 2025, driven by strong growth across all products and disciplined execution. 2026 guidance projects over 30% revenue growth, with major investments in pipeline and commercial expansion, while maintaining positive Adjusted EBITDA.
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Why Are Shares Of Xeris Biopharma Falling Friday?
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) are falling Friday after the company announced a patent infringement lawsuit to protect its drug, Recorlev.
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our ...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant revenue growth and profitability have enabled reinvestment in commercial expansion, especially for Recorlev, which is positioned as a key growth driver with robust IP protection. Gvoke and Keveyis maintain stable performance, while pipeline asset XP-8121 targets a large unmet need. Commercial infrastructure is highly leverageable for future launches.
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025
Q3 saw record revenue growth of 40% year-over-year, with Recorlev leading at 109% growth and the company achieving its first-ever net income. Full-year guidance was raised, and major commercial expansion and pipeline progress position the business for continued strong growth.
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Strong revenue growth and high margins enable self-funded expansion, with Recorlev® and XP8121 as top priorities. Recorlev® targets a billion-dollar market, while XP8121 addresses a large unmet need with a phase 3 trial planned. Commercial scaling and innovation drive long-term growth.
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Earnings Call Transcript: Q2 2025
Q2 revenue grew 49% year-over-year to a record $71.5 million, driven by strong demand for all products, especially Recorlev. Full-year 2025 revenue guidance was raised to $280–$290 million, with continued investment in commercial expansion and pipeline assets.
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2025
Strong commercial growth is driven by Recorlev, with ambitious long-term revenue targets and a robust pipeline. Gvoke and Keveyis support near-term growth, while XP-8121 targets a large unmet need in hypothyroidism, aiming for approval by 2030.
Xeris Biopharma Holdings Transcript: Investor Day 2025
Management outlined a strategy for accelerated growth, targeting $750M revenue by 2030 and multi-billion dollar status by 2035, led by Recorlev and XP-8121. Recorlev is positioned for $1B in annual sales, while XP-8121 aims to address a large unmet need in hypothyroidism with a pivotal study starting in 2026.
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Details for Analyst & Investor Day
CHICAGO--(BUSINESS WIRE)--Xeris Announces Details for Analyst & Investor Day.